Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26391-26400 Newer>

The Motley Fool September 28, 2007 Brian Orelli	Free Drugs From Merck Merck plans to donate enough of its Gardasil vaccine to vaccinate one million women, in some of the poorest countries in the world, against the human papilloma virus.
The Motley Fool September 28, 2007 Toby Shute	A Gold Giant's Grim Guidance Newmont Mining reveals in an SEC filing that its costs may exceed previous guidance.
The Motley Fool September 28, 2007 Dave Mock	Weekly Market Recap: Telecom Edition MySpace is coming to cell phones... Struggling Earthlink lets SK Telecom pay for their joint Helio venture... Virgin Mobile gets ready for its IPO... A bad week for Vonage...
The Motley Fool September 28, 2007 Tom Taulli	Software's $31 Billion Megatrend Cyber security continues to be a huge problem, but it's a great opportunity for some software vendors. Investors, take note.
The Motley Fool September 28, 2007 Brian Lawler	GSK Helps Secure Future of a Lead Drug GlaxoSmithKline settles a patent infringement case on a lead drug, Avandia, and with that challenger gone, the company is a step closer to securing one of its top franchises.
The Motley Fool September 28, 2007 Michael Goode	AZZ Good as It Gets For the last three years, the electrical products and steel-galvanizing company has ridden the wave of increased infrastructure spending in the U.S. and China, and its revenue and earnings have soared.
The Motley Fool September 28, 2007 Mac Greer	Fool Video: Will Crocs Stay Hot? Will Crocs stay hot? Could it be the next Deckers Outdoor or Heelys? These and other questions about the shoemaker are discussed in this video.
The Motley Fool September 28, 2007 Brian Lawler	Bioenvision Shareholder Battle Genzyme announces that it "cannot and will not" raise its $5.60-a-share bid for Bioenvision before shareholders go to vote on its proposed takeover. Investors, take note.
The Motley Fool September 28, 2007 Brian Orelli	Idenix Axes Ailing Initiatives The small drug developer drops its hepatitis B program, deciding instead to focus on its HCV and HIV drug development. Investors, take note.
The Motley Fool September 28, 2007 David Lee Smith	Losses Building Up at KB KB Home's massive quarterly losses were softened, a little, by the sale of their French subsidiary.
<Older 26391-26400 Newer> Return to current articles.